ABSTRACT
Objectives Obtaining body temperature is a quick and easy method to screen for acute infection such as COVID-19. Currently, the predictive value of body temperature for acute infection is inhibited by failure to account for other readily available variables that affect temperature values. In this proof-of-concept study, we sought to improve COVID-19 pretest probability estimation by incorporating covariates known to be associated with body temperature, including patient age, sex, comorbidities, month, time of day.
Methods For patients discharged from an academic hospital emergency department after testing for COVID-19 in March and April of 2020, we abstracted clinical data. We reviewed physician documentation to retrospectively generate estimates of pretest probability for COVID-19. Using patients’ COVID-19 PCR test results as a gold standard, we compared AUCs of logistic regression models predicting COVID-19 positivity that used: 1) body temperature alone; 2) body temperature and pretest probability; 3) body temperature, pretest probability, and body temperature-relevant covariates. Calibration plots and bootstrap validation were used to assess predictive performance for model #3.
Results Data from 117 patients were included. The models’ AUCs were: 1) 0.69 2) 0.72, and 3) 0.76, respectively. The absolute difference in AUC was 0.029 (95%CI −0.057 to 0.114, p=0.25) between model 2 and 1 and 0.038 (95%CI −0.021 to 0.097, p=0.10) between model 3 and 2.
Conclusions By incorporating covariates known to affect body temperature, we demonstrated improved pretest probability estimates of acute COVID-19 infection. Future work should be undertaken to further develop and validate our model in a larger, multi-institutional sample.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by Cedars-Sinai Precision Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study procedures were reviewed and approved by the Institutional Review Board at Cedars-Sinai Medical Center. Office of Research Compliance and Quality Improvement, 6500 Wilshire Blvd., Suite 1800, Los Angeles, CA 90048
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon request, and only after permission from the Cedars-Sinai Medical Center Institutional Review Board.
